Vistagen Therapeutics (NASDAQ:VTGN) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Vistagen Therapeutics (NASDAQ:VTGN) released its quarterly earnings data on Thursday. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.02, Zacks reports. The firm had revenue of $230 billion during the quarter, compared to the consensus estimate of $0.18 million. Vistagen Therapeutics had a negative return on equity of 36.35% and a negative net margin of 4,521.71%.

Vistagen Therapeutics Stock Performance

Shares of NASDAQ VTGN traded up $0.12 during midday trading on Friday, hitting $2.97. 265,723 shares of the stock traded hands, compared to its average volume of 174,465. The business has a 50 day moving average price of $2.81 and a two-hundred day moving average price of $2.99. Vistagen Therapeutics has a one year low of $2.22 and a one year high of $5.74. The company has a market cap of $82.68 million, a PE ratio of -2.40 and a beta of 0.77.

About Vistagen Therapeutics

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.